Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 7/20 | 0.71 |
| ▸ | CDK7 | P50613 | 5/20 | 0.71 |
| ▸ | CDK9 | P50750 | 5/20 | 0.71 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.71 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 3/20 | 0.48 |
| ▸ | IGF1R | P08069 | 3/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.48 |
| ▸ | WEE1 | P30291 | 2/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2085358 | 0.84 | CDK2 (1.00) | CDK2CDK7CDK9CCNT1MKNK2 | |
| SCHEMBL2076008 | 0.81 | CDK2 (0.81) | CDK2CDK7CDK9CCNT1MKNK2 | |
| SCHEMBL2087938 | 0.80 | CDK2 (0.75) | CDK2CDK7CDK9CCNT1MKNK2 | |
| SCHEMBL18454477 | 0.79 | CDK4 (0.66) | CDK2CDK7CDK9CCNT1CCNE1 | |
| SCHEMBL29815786 | 0.79 | CDK4 (0.66) | CDK2CDK7CDK9CCNT1CCNE1 | |
| SCHEMBL2087408 | 0.76 | CDK2 (0.63) | CDK2CDK7CDK9CCNT1MKNK2 | |
| SCHEMBL2076613 | 0.73 | CDK2 (0.80) | CDK2CDK7CDK9CCNT1MKNK2 | |
| SCHEMBL2087906 | 0.72 | CDK2 (0.75) | CDK2CDK7CDK9CCNT1CCNE1 | |
| SCHEMBL2088831 | 0.71 | CDK2 (0.72) | CDK2CDK7CDK9CCNT1CCNE1 | |
| SCHEMBL2087314 | 0.71 | CDK2 (0.71) | CDK2CDK7CDK9CCNT1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | CDK2 459/4885CDK7 1077/4885CDK9 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.